Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Sustainable complete remission in recurrence yolk sac tumor patient treated with tandem high-dose chemotherapy and autologous stem cell
1Department of Obstetrics & Gynecology, Sultanah Bahiyah Hospital, Kedah (Malaysia)
2Division of Hematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Kwei-Shan, Tao-Yuan (Taiwan)
3Department of Obstetrics and Gynecology Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Kwei-Shan, Tao-Yuan (Taiwan)
4Department of Obstetrics and Gynecology. University Malaya Medical Center, Faculty of Medicine, University of Malaya, Kuala Lumpur (Malaysia)
5Department of Obstetrics & Gynecology, Centro Hospitalar do Porto, Porto (Portugal)
*Corresponding Author(s): K. G. Huang E-mail: kghuang@ms57.hinet.net
A 21-year-old lady diagnosed with Stage 3 ovarian yolk sac tumor (YST) underwent primary cytoreductive fertility sparing surgery, followed by conventional courses of platinum-based chemotherapy and etoposide. Recurrence at cul-da-sac was noted after a short period of remission and secondary debulking performed followed by four cycles of conventional chemotherapy. The patient’s disease progressed despite courses of treatments. A joint team management including a hematologist was commenced following the failure of conventional chemotherapies. Two cycles of high-dose chemotherapy (HDCT) with ifosfamide/cisplatin/etoposide (ICE) regimen, followed by autologous stem cell transplantation (ASCT) were given. With this salvage treatment, she remained in complete remission and disease-free for more than 30 months, while maintaining her reproductive function. These approaches appear to be effective as a salvage treatment in selected cases of patients with ovarian germ cell tumor, especially those who failed primary conventional chemotherapy.
High-dose chemotherapy; Germ cell tumor; Autologous stem cell.
N. A. Abdullah,P. N. Wang,K. G. Huang,A. S. Adlan,J. Casanova. Sustainable complete remission in recurrence yolk sac tumor patient treated with tandem high-dose chemotherapy and autologous stem cell. European Journal of Gynaecological Oncology. 2013. 34(2);183-185.
[1] Dallenbach P., Bonnefoi H., Pelte M.F., Vlastos G.: “Yolk sac tumours of the ovary: an update”. Eur. J. Surg. Oncol., 2006, 32, 1063.
[2] Pestasides D., Pectasides E., Kassanos D.: “Germ cell tumor of ovary”. Cancer Treat. Rev., 2008, 34, 427.
[3] El-Helw L., Coleman R.E.: “Salvage, dose intense and high-dose chemotherapy for the treatment of poor prognosis or recurrent germ cell tumours’. Cancer Treat. Reviews, 2005, 31, 197.
[4] de La Motte Rouge T., Pautier P., Rey A., Duvillard P., Kerbrat P., Troalen F. et al.: “Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases”. Eur. J. Cancer, 2011, 47, 175. Epub 2010 Sep. 28.
[5] Li J., Yang W., Wu X.: “Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients”. Gynecol. Oncol., 2007, 105, 769.
[6] Mitchell P.L., Al-Nasiri N., A’Hern R., Fisher C., Horwich A., Pinkerton C.R. et al.: “Treatment of nondysgerminomatous ovarian germ cell tumors: an analysis of 69 cases”. Cancer, 1999, 85, 2232.
[7] Connolly R.M., McCaffrey J.A.: “High-dose chemotherapy plus stem cell transplantation in advanced germ cell cancer: a review”. Eur. Urol., 2009, 56, 57.
[8] Rick O., Siegert W., Beyer J.: “Chemotherapy in patients with metastatic or relapsed germ-cell tumours”. Cancer Treat. Rev., 2001, 27, 283.
[9] Kondagunta G.V., Bacik J., Sheinfeld J., Bajorin D., Bains M., Reich L. et al.: “Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors”. J. Clin. Oncol., 2007, 25, 85.
[10] Einhorn L.H., Williams S.D., Chamness A. et al.: “High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors”. NEJM, 2007, 357, 340.
Top